Evidence map›Paper›PMID 31780862›Full record

ArticleMediators of inflammation2019

Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis.

Yuxuan Li, Lin Yuan, Jie Yang, Yue Lei, Hui Zhang, Liping Xia, Hui Shen, Jing Lu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediators of inflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. The JAK/STAT signaling pathway: from bench to clinic.Signal transduction and targeted therapy · 2021
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yuxuan LiDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, China.
Lin YuanDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, China.
Jie YangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, China.
Yue LeiDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, China.
Hui ZhangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, China.
Liping XiaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, China.
Hui ShenDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, China.
Jing LuDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, China.ORCID https://orcid.org/0000-0003-3501-1749
First Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTofacitinib is a novel therapy for rheumatoid arthritis (RA). The aim of this study was to measure various serum cytokines levels and to explore potential markers predictive of therapeutic efficacy of tofacitinib for RA patients.

methodsThirty-two patients with RA were given tofacitinib (5 mg bid). Serum cytokines levels of Th1 (IFN-

resultsDisease activity was significantly decreased as early as week 4 after tofacitinib treatment. Serum IL-35 levels were significantly increased and serum levels of TNF-

conclusionsAfter treatment with tofacitinib, RA patients may benefit from monitoring of disease activity as early as week 4. IL-35 also might be a predictive indicator of the disease activity and drug efficacy. Meanwhile, tofacitinib might be CS-sparing in RA.

Indexed as

AdultArthritis, RheumatoidCytokinesFemaleHumansInterleukin-17Interleukin-6InterleukinsMaleMiddle AgedPiperidinesPyrimidinesPyrrolesTumor Necrosis Factor-alphaCytokinesInterleukin-17interleukin-35, humanInterleukin-6InterleukinsPiperidinesPyrimidinesPyrrolestofacitinibTumor Necrosis Factor-alpha

Identifiers

PMID31780862
PMCPMC6855066
OpenAlexW2981455539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.